Business
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under
About this update from Invo Fertility, Inc.
[{"type":"image","alt":"INVO Fertility, Inc.","displaySize":"","headline":null,"caption":"INVO Fertility, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/7597264acf7f316bc005ac3aa107b273"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bAHKwoixsVIBdBGpWthJUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7597264acf7f316bc005ac3aa107b273","width":300,"height":70}},"lazy":false},{"type":"text","content":"SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the “Offering”). The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $1.69. The warrants will have an exercise price of $1.69 per share, will be exercisable upon shareholder approval and will expire on the five year anniversary from such date of shareholder approval.","length":868,"tagName":"p"},{"type":"text","content":"The gross proceeds to the Company from the Offering are estimated to be approximately $4.0 million before deducting the placement agent’s fees and other estimated Offering expenses. The Offering is expected to close on or about December 3, 2025, subject to the satisfaction of customary closing conditions.","length":306,"tagName":"p"},{"type":"text","content":"Maxim Group LLC is acting as the sole placement agent in connection with the Offering.","length":86,"tagName":"p"},{"type":"text","content":"The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pur...